First New York Securities’s Impax Laboratories, Inc. IPXL Stock Holding History

First New York Securities’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-5,000	Closed	-$132K	–	425
2014 Q1	$132K	Buy	+5,000	New	+$125K	0.06%	192

Other funds holding IPXL

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

First New York Securities's IPXL Position: Q2 2014 in Review

First New York Securities sold out of Impax Laboratories, Inc. (IPXL) in Q2 2014, closing a stake of 5,000 shares — an estimated $132K sold.

First New York Securities first reported a position in IPXL in Q1 2014 and held it in 1 quarter. The position peaked at $132K in Q1 2014. 185 funds tracked by Wall St. Rank hold IPXL as of Q2 2014.

First New York Securities reported no remaining Impax Laboratories, Inc. position as of Q2 2014 after selling out during the quarter.
First New York Securities sold 5,000 Impax Laboratories, Inc. shares in Q2 2014, an estimated $132K.
First New York Securities first reported a position in Impax Laboratories, Inc. in Q1 2014 and held it in 1 quarter.
First New York Securities's Impax Laboratories, Inc. position peaked at $132K in Q1 2014.
185 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2014.

Based on First New York Securities's 13F filing for Q2 2014, filed 15 Aug 2014.